Brief: Kamada Announces Additional Interim Results From Phase 2 Proof Of Concept Clinical Trial Of Intravenous Alpha-1 Antitrypsin Treatment
06/02/2019 12:07
Feb 6 (Reuters) - Kamada Ltd KMDA.TA :
* KAMADA ANNOUNCES ADDITIONAL INTERIM RESULTS FROM PHASE 2
PROOF
OF CONCEPT CLINICAL TRIAL OF INTRAVENOUS ALPHA-1 ANTITRYPSIN
TREATMENT FOR PREVENTION OF LUNG TRANSPLANT REJECTION
* KAMADA LTD - TOP-LINE RESULTS ANTICIPATED IN H2 2019
* KAMADA LTD - KAMADA'S IV-AAT DEMONSTRATED A TREND TOWARDS
IMPROVEMENTS IN MULTIPLE CLINICAL OUTCOMES
* KAMADA LTD - NONE OF ADVERSE EVENTS (AES) OR SERIOUS
ADVERSE
EVENTS (SAES) OBSERVED TO DATE WERE CONSIDERED TO BE RELATED TO
TREATMENT WITH IV-AAT.
Source text for Eikon: ID:nGNX6mb9Ll
Further company coverage: KMDA.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kamada
See all newsBrief: Kamada Updates On Withholding Tax Procedures On Previously Announced Cash Dividend To Shareholders
Brief: Kamada Announces Planned Transition Of Chief Financial Officer
Brief: Kamada Q2 EPS USD 0.16
Brief: Kamada Announces FDA Approval Of Its New In-House Rabies Virus Neutralization Testing Laboratory
Brief: Kamada Q4 EPS USD 0.06